Serina Therapeutics reports Cohort 1 observations and advances to Cohort 2
Serina Therapeutics said it has reported Cohort 1 observations from its Ser-252 registrational study in advanced Parkinson’s disease and has advanced to Cohort 2.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.